As of 2023, Thomas Gad owns options to purchase 75,000 shares of Y-mAbs Therapeutics stock as part of his interim CEO compensation. He received this grant after serving as interim CEO and aims to align his interests with those of...

As of 2023, Thomas Gad owns options to purchase 75,000 shares of Y-mAbs Therapeutics stock as part of his interim CEO compensation. He received this grant after serving as interim CEO and aims to align his interests with those of the shareholders. Prior to 2023, he had no vested stock, focusing primarily on performance-based cash incentives that reflected the company’s achievements. His holdings reflect not just personal investment in the company but also aim to foster growth in an innovative space. This move signals his long-term commitment and belief in the company’s future potential, despite the company's stock price fluctuations over the years. During his tenure, his wealth was primarily tied up in a range of compensation rather than direct stock holdings, emphasizing a performance-oriented focus.